EYEG Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	10 000.00
Średni wolumen	469.00
Kapitalizacja rynkowa	64.23M
EPS	$-0.420 ( 2021-11-08 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-19.65
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-02	From Stephen	Sell	250	Common Stock
2021-11-02	Mann Brenda	Sell	62	Common Stock
2021-10-04	Mann Brenda	Sell	62	Common Stock
2021-10-04	From Stephen	Sell	249	Common Stock
2021-09-02	From Stephen	Sell	253	Common Stock

INSIDER POWER
0.00
Last 98 transactions
Buy: 1 959 813 \| Sell: 207 057

EyeGate Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
BMTC	0.948
XPDI	0.926
FATE	0.912
TCDA	0.908
GRAY	0.905
ENPH	0.896
BCAB	0.895
ODT	0.887
HECCU	0.884
LHDX	0.879

10 Najbardziej negatywne korelacje
TIG	-0.936
CCRC	-0.928
FRGI	-0.917
ARNA	-0.903
DSPG	-0.899
ACIW	-0.899
NTES	-0.896
EXAS	-0.896
APEN	-0.896
GGAL	-0.895

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

EyeGate Pharmaceuticals Finanse

Annual	2020
Przychody:	$12 059.00
Zysk brutto:	$12.06 (0.10 %)
EPS:	$-2.54

FY	2020
Przychody:	$12 059.00
Zysk brutto:	$12.06 (0.10 %)
EPS:	$-2.54

FY	2019
Przychody:	$2.69M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.23

FY	2018
Przychody:	$1.65M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-4.50

Financial Reports:

No articles found.

EyeGate Pharmaceuticals

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.